p53 Prions - Novel Biomarker for Circulating Tumor Cells

Patent-pending Test Kit by OncoLab Launched. Novel tests by OncoLab (Austria) identify cancer cells via p53 prions.
By: OncoLab Diagnostics GmbH
WIENER NEUSTADT, Austria - Sept. 23, 2021 - PRLog -- -       p53 aggregates frequently present in circulating tumor cells (CTC)

-       Novel tests by OncoLab (Austria) identify cancer cells via p53 prions

-       Kits for use with tissues, cells, and blood available

-       OncoLab's range of IF and PCR-based circulating rare cell (CRC) detection kits extended

Wiener Neustadt (Austria), September 22nd, 2021. A patent-pending new technology allows more reliable identification of circulating tumor cells (CTC). The technology is based on the identification of p53 aggregates ("p53 prions") using Blood-based Biopsy tests (BBB) developed by OncoLab GmbH, Austria. p53 is a well-known tumor suppressor protein. Mutations of the gene can cause prion-like aggregation of p53-proteins. OncoLab has developed tests for amplified immuno-labeling of these aggregates using proprietary technology of Navinci Diagnostics AB, the Swedish specialist for visualizing proteins and their protein-protein interactions and post-translational modifications.

Besides p53 aggregates the OncoLab's CTC test "nPACTM AMYLOplexTM CTC-p53" also detects known CTC markers (several cytokeratins) as well as leucocyte markers. It is based on immunofluorescence, a method that allows a direct identification of CTCs and provides information about the morphology and numbers of CTCs. Immunofluorescence staining is also used in OncoLab's "nPACTM CRC IF" series of tests that is offered in collaboration with US-based AxonDx, LLC.

About OncoLab Diagnostics GmbH (September 2021)

OncoLab develops, manufactures and distributes innovative and precise diagnostic tests with a focus on Blood-based Biopsy tests. Products are available for detecting circulating tumor, endothelial and stromal cells as well as immune cells. The company is certified according to ISO 9001:2015 and ISO 13485:2016 and member of the International Society of Liquid Biopsy (ISLB) and the European Liquid Biopsy Society (ELBS).


Email:***@prd.at Email Verified
Location:Wiener Neustadt - Lower Austria - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share